Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener
We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...
635 Views
Primer: Sawai Group Holdings (4887 JP) - Aug 2026
Sawai Group Holdings is a leading generic pharmaceutical company in Japan, facing a challenging domestic market characterized by...
98 Views
Nippon Shinyaku (4516 JP): FY27 Guidance Signals Recovery, Speed Bumps Remain
Nippon Shinyaku's FY26 revenue grew 7% to ¥170B, driven by ethical drugs and higher licensing fees. FY27 revenue expected to reach ¥200B with...
121 Views
Kaken Pharma (4521 JP): Growth Pangs Continue in 9MFY26, Guidance Marginally Revised
Kaken Pharmaceutical (4521 JP) reports underwhelming earnings in 9MFY26. Company needs strong revenue driver to combat challenges from drug price...
173 Views
Kaken Pharma (4521 JP): Bleaker FY26 Ahead, Growth Pangs to Continue for Now
Kaken Pharmaceutical (4521 JP) reports underwhelming H1FY26 earnings with significant drops in revenue and profit. Needs strong revenue driver to...
312 Views